Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
San Raffaele Telethon Institute for Gene Therapy is developing an adenosine deaminase-transduced hematopoietic stem cell therapy for the potential intravenous treatment of adenosine deaminase deficiency in severe combined immunocompromised individuals.